VIDEO: Neurotech Pharmaceuticals offers macular telangiectasia education at AAO
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Richard Small, CEO of Neurotech Pharmaceuticals, provides a company update ahead of the American Academy of Ophthalmology Meeting.
Neurotech submitted a biologics license application for its macular telangiectasia therapy, NT-501, to the FDA in April, Small said. As Healio previously reported, NT-501 was granted priority review by the FDA in June. The therapy’s PDUFA review date is set for December of this year.
The company is also hosting a new medical education program at their AAO exposition booth this year, which will feature information on macular telangiectasia.
“We’re going to be offering some education around the disease that we’re treating,” he said. “We all look forward to seeing you.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts